SPL 9.20% 9.5¢ starpharma holdings limited

Ann: Positive final DEP irinotecan Phase 2 clinical trial results, page-16

  1. 2,834 Posts.
    lightbulb Created with Sketch. 138
    Well @thrasher perhaps you could end up being right. A quote from today's SPL announcement:

    "Both products are supported by a strong international intellectual property portfolio, and Starpharma is looking to license global rights to DEP® irinotecan and DEP® cabazitaxel to a partner with the expertise to maximise their clinical and commercial potential."

    Anything could be possible. Will be interesting to see how these results are received at ASCO.


 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
0.008(9.20%)
Mkt cap ! $39.14M
Open High Low Value Volume
9.0¢ 9.5¢ 8.8¢ $334.2K 3.710M

Buyers (Bids)

No. Vol. Price($)
2 50354 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
9.5¢ 22908 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.